reviewTop 1% cited
Can the pharmaceutical industry reduce attrition rates?
Nature Reviews Drug Discovery · 2004 · Vol. 3(8) · pp. 711–716
Ismail Kola✉(Merck & Co., Inc., Rahway, NJ, USA (United States))J. Richard Landis(AIL Research (United States))
Pharmaceutical Economics and PolicyBiosimilars and Bioanalytical MethodsBiotechnology and Related FieldsPharmaceutical industryScrutinyAttritionProductivitySubject (documents)PoliticsPerspective (graphical)Face (sociological concept)Public economicsHealth care
MeSH terms
Clinical Trials as TopicDrug IndustryHumansPharmacokineticsDrug DesignDrug Approval
Citations
4,081
FWCI
281.33
field-weighted impact
References
7
Percentile
100%
vs. same field & year
Citations per year
Cited by
The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology
Oncotarget · 2016 · 362 citations
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Journal of Medicinal Chemistry · 2008 · 1,103 citations
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Journal of Medicinal Chemistry · 2011 · 2,642 citations
Fast Dissolving Curcumin Cocrystals
Crystal Growth & Design · 2011 · 246 citations
Molecular Docking: Shifting Paradigms in Drug Discovery
International Journal of Molecular Sciences · 2019 · 2,141 citations
A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Lab on a Chip · 2010 · 470 citations
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Nature Biotechnology · 2015 · 6,477 citations
Model-based Drug Development
Clinical Pharmacology & Therapeutics · 2007 · 437 citations
References
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics
Human Molecular Genetics · 2001 · 703 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.